Product Introduction: ROZUTIN - F

ROZUTIN - F is a powerful combination lipid-regulating tablet manufactured by Knoll. Combining 10mg of Rosuvastatin (an HMG-CoA reductase inhibitor) and 160mg of Fenofibrate (a fibric acid derivative), it targets multiple lipid abnormalities, providing comprehensive dyslipidemia management.

Primary Indications

• Management of mixed dyslipidemia and severe hypertriglyceridemia.
• Lowering elevated total cholesterol, LDL-C, apolipoprotein B, and triglycerides while raising HDL-C.
• Reducing cardiovascular risk in patients with combined lipid disorders.

Therapeutic Benefits

• Comprehensive Lipid Control: Rosuvastatin reduces bad cholesterol (LDL), while Fenofibrate effectively targets triglycerides.
• HDL Improvement: Synergistic action raises good cholesterol (HDL) levels.
• Plaque Stability: Protects blood vessels from fatty deposit buildup and vessel narrowing.

Possible Side Effects

Common side effects may include:

• Digestive issues, such as nausea, abdominal pain, flatulence, or diarrhea.
• Musculoskeletal pain, back pain, or joint stiffness.
• Increased liver enzyme levels (reversible upon discontinuation).

How to Take ROZUTIN - F

• Take one tablet daily, preferably with a meal to improve Fenofibrate absorption.
• Swallow the tablet whole with a glass of water. Do not crush or chew.
• Adhere to a low-fat, low-cholesterol diet to support the medication's effect.

Mechanism of Action

ROZUTIN - F works through two complementary lipid-lowering mechanisms:

• Rosuvastatin: Inhibits HMG-CoA reductase, decreasing cholesterol production in the liver and clearing LDL cholesterol from the blood.
• Fenofibrate: Activates peroxisome proliferator-activated receptor alpha (PPAR-alpha), which increases the lipolysis and clearance of atherogenic triglyceride-rich particles.

Safety Warnings

• Pregnancy & Nursing: Strictly contraindicated. Avoid use if pregnant or planning to become pregnant.
• Liver & Kidney Health: Contraindicated in patients with active liver disease, gallbladder disease, or severe renal impairment.
• Myopathy Risk: Combined statin-fibrate therapy increases the risk of muscle toxicity. Report muscle pain immediately.

Patient Advice

• Maintain regular blood tests as recommended by your physician to monitor lipid levels, kidney, and liver health.
• Report any unexplained muscle pain, tenderness, or weakness immediately.
• Do not stop taking this medication without consulting your doctor.

Fact Box

Drug Interactions

• Cyclosporine: Significantly increases Rosuvastatin exposure and side effect risks.
• Oral Anticoagulants (Warfarin): May enhance the anticoagulant effect, increasing bleeding risks.
• Colchicine: Concomitant use increases the risk of myopathy.

User Feedback

• Patients report significant reductions in both cholesterol and triglyceride levels within 4 to 8 weeks.
• Highly recommended by cardiologists for comprehensive dyslipidemia management.